NPY/Y1 receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension

British Journal of Pharmacology

Volumn 171, Issue 16, 2014, Pages 3895-3907

  Crnkovic, S ^a,b   Egemnazarov, B ^a   Jain, P ^a   Seay, U ^c   Gattinger, N ^c   Marsh, L M ^a   Balint Z ^a   Kovacs, G ^a,b   Ghanim, B ^a,d   Klepetko, W ^d   Schermuly, R T ^c   Weissmann, N ^c   Olschewski, A ^a,b   Kwapiszewska, G ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CALCIUM; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCROTALINE; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; PROTEIN KINASE D; SEMAXANIB; ARGININE; INDOLE DERIVATIVE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR; PYRROLE DERIVATIVE; VASOCONSTRICTOR AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CALCIUM CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; SYMPATHETIC INNERVATION; VASOCONSTRICTION; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; FEMALE; GENETICS; IN VITRO STUDY; LUNG; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; YOUNG ADULT;

ADULT; ANIMALS; ANOXIA; ARGININE; CELL PROLIFERATION; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IN VITRO TECHNIQUES; INDOLES; LUNG; MALE; MICE, INBRED C57BL; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; NEUROPEPTIDE Y; PULMONARY ARTERY; PYRROLES; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84904965618     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12751     Document Type: Article

References (45)

1. Abe K, Tilan JU, Zukowska Z, (2007). NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 7: 1704-1709.
2. Abedi H, Rozengurt E, Zachary I, (1998). Rapid activation of the novel serine/threonine protein kinase, protein kinase D by phorbol esters, angiotensin II and PDGF-BB in vascular smooth muscle cells. FEBS Lett 427: 209-212.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Allen KM, Wharton J, Polak JM, Haworth SG, (1989). A study of nerves containing peptides in the pulmonary vasculature of healthy infants and children and of those with pulmonary hypertension. Br Heart J 62: 353-360.
5. Balint Z, Zabini D, Konya V, Nagaraj C, Vegh AG, Varo G, et-al. (2013). Double-stranded RNA attenuates the barrier function of human pulmonary artery endothelial cells. PLoS ONE 8: e63776.
6. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et-al. (2013). Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 62: 1092-1100.
7. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P, (2010). Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 181: 1269-1275.
8. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, et-al. (2006). Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113: 286-295.
9. Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R, (2000). Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol 78: 116-125.
10. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F, (1984). Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 8: 225-235.
11. El-Haroun H, Clarke DL, Deacon K, Bradbury D, Clayton A, Sutcliffe A, et-al. (2008). IL-1beta, BK, and TGF-beta1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. Am J Physiol Lung Cell Mol Physiol 294: L553-L562.
12. Fink L, Stahl U, Ermert L, Kummer W, Seeger W, Bohle RM, (1999). Rat porphobilinogen deaminase gene: a pseudogene-free internal standard for laser-assisted cell picking. Biotechniques 26: 510-516.
13. Geng J, Zhao Z, Kang W, Wang W, Liu G, Sun Y, et-al. (2009). Hypertrophic response to angiotensin II is mediated by protein kinase D-extracellular signal-regulated kinase 5 pathway in human aortic smooth muscle cells. Biochem Biophys Res Commun 388: 517-522.
14. Goldman WF, Wier WG, Blaustein MP, (1989). Effects of activation on distribution of Ca2+ in single arterial smooth muscle cells. Determination with fura-2 digital imaging microscopy. Circ Res 64: 1019-1029.
15. Hao F, Wu DD, Xu X, Cui MZ, (2012). Histamine induces activation of protein kinase D that mediates tissue factor expression and activity in human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 303: H1344-H1352.
16. Hislop A, Reid L, (1977). Changes in the pulmonary arteries of the rat during recovery from hypoxia-induced pulmonary hypertension. Br J Exp Pathol 58: 653-662.
17. Holler J, Zakrzewicz A, Kaufmann A, Wilhelm J, Fuchs-Moll G, Dietrich H, et-al. (2008). Neuropeptide Y is expressed by rat mononuclear blood leukocytes and strongly down-regulated during inflammation. J Immunol 181: 6906-6912.
18. Jacques D, Sader S, El-Bizri N, Chouffani S, Hassan G, Shbaklo H, (2000). Neuropeptide Y induced increase of cytosolic and nuclear Ca2+ in heart and vascular smooth muscle cells. Can J Physiol Pharmacol 78: 162-172.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Troster N, et-al. (2009). Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 180: 881-886.
21. Kummer W, (2011). Pulmonary vascular innervation and its role in responses to hypoxia: size matters! Proc Am Thorac Soc 8: 471-476.
22. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Trosser R, Wilhelm J, et-al. (2008). Fhl-1, a new key protein in pulmonary hypertension. Circulation 118: 1183-1194.
23. Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, et-al. (2012). The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE 7: e43433.
24. Lobaugh LA, Blackshear PJ, (1990). Neuropeptide Y stimulation of myosin light chain phosphorylation in cultured aortic smooth muscle cells. J Biol Chem 265: 18393-18399.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. MacLean MR, Morecroft I, (2001). Increased contractile response to 5-hydroxytryptamine1-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br J Pharmacol 134: 614-620.
27. de Man FS, Handoko ML, Guignabert C, Bogaard HJ, Vonk-Noordegraaf A, (2013). Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe? Am J Respir Crit Care Med 187: 14-19.
28. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et-al. (2009). Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-S31.
29. Morrell NW, Archer SL, Defelice A, Evans S, Fiszman M, Martin T, et-al. (2013). Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ 3: 226-244.
30. Nagaraj C, Tang B, Balint Z, Wygrecka M, Hrzenjak A, Kwapiszewska G, et-al. (2013). Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 41: 85-95.
31. Painsipp E, Sperk G, Herzog H, Holzer P, (2010). Delayed stress-induced differences in locomotor and depression-related behaviour in female neuropeptide-Y Y1 receptor knockout mice. J Psychopharmacol 24: 1541-1549.
32. Pons J, Lee EW, Li L, Kitlinska J, (2004). Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases. Curr Opin Investig Drugs 5: 957-962.
33. Pons J, Kitlinska J, Jacques D, Perreault C, Nader M, Everhart L, et-al. (2008). Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Can J Physiol Pharmacol 86: 438-448.
34. Reynolds EE, Yokota S, (1988). Neuropeptide Y receptor-effector coupling mechanisms in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 151: 919-925.
35. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et-al. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
36. Shen B, Cheng KT, Leung YK, Kwok YC, Kwan HY, Wong CO, et-al. (2008). Epinephrine-induced Ca2+ influx in vascular endothelial cells is mediated by CNGA2 channels. J Mol Cell Cardiol 45: 437-445.
37. Shigeri Y, Fujimoto M, (1993). Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 149: 19-22.
38. Shigeri Y, Nakajima S, Fujimoto M, (1995). Neuropeptide YY1 receptors-mediated increase in intracellular Ca2+ concentration via phospholipase C-dependent pathway in porcine aortic smooth muscle cells. J Biochem 118: 515-520.
39. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et-al. (2012). Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 261-272.
40. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P, (2004). Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110: 1308-1312.
41. Weisel FC, Kloepping C, Pichl A, Sydykov A, Kojonazarov B, Wilhelm J, et-al. (2014). Impact of s-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling. Circulation 129: 1510-1523.
42. Wier WG, Zang WJ, Lamont C, Raina H, (2009). Sympathetic neurogenic Ca2+ signalling in rat arteries: ATP, noradrenaline and neuropeptide Y. Exp Physiol 94: 31-37.
43. Xu X, Ha CH, Wong C, Wang W, Hausser A, Pfizenmaier K, et-al. (2007). Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol 27: 2355-2362.
44. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H, (1998a). Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75-76: 231-238.
45. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et-al. (1998b). Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83: 187-195.